Skip Navigation



JAC Advance Access published online on June 12, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg288
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/123    most recent
dkg288v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Richter, S. S.
Right arrow Articles by Doern, G. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richter, S. S.
Right arrow Articles by Doern, G. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species

S. S. Richter 1 , D. E. Kealey 1 , C. T. Murray 1 , K. P. Heilmann 1 , S. L. Coffman 1 , and G. V. Doern 1

1 Department of Pathology, C606 GH, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242-1009, USA

Received 13 January 2003 ; revised 14 April 2003 ; accepted 15 April 2003

Abstract

Objective: The purpose of this study was to examine the in vitro activity of daptomycin using an optimal calcium (Ca2+) concentration (50 mg/L) against a diverse collection of enterococcal and Staphylococcus aureus clinical isolates, including glycopeptide-resistant enterococci (GRE) and methicillin-resistant S. aureus (MRSA).

Methods: The activity of daptomycin was compared with the activities of seven other agents against 1483 enterococcal and S. aureus clinical isolates, including 303 GRE and 193 methicillin-resistant S. aureus (MRSA) strains. Susceptibility testing was performed by the NCCLS broth microdilution method, with one exception: Mueller-Hinton (MH) broth was supplemented to a physiological level of 50 mg/L Ca2+ when testing daptomycin. Daptomycin zone diameters were determined by disc diffusion with MH agar plates containing Ca2+ 50 mg/L.

Results: All staphylococcal isolates tested, and the majority of enterococcal isolates (96.5%), would be considered susceptible to daptomycin if the breakpoint previously proposed of <=2 mg/L was applied. The activity of daptomycin against MRSA and methicillin-susceptible S. aureus was essentially equal. Daptomycin also had similar activity against GRE and glycopeptide-susceptible enterococci. Every S. aureus isolate had a daptomycin zone diameter >=20 mm, and all of the enterococcal isolates had daptomycin zone diameters >=17 mm.

Conclusions: Overall, daptomycin showed potent activity against S. aureus and enterococcal isolates, comparable to quinupristin-dalfopristin and linezolid.

Keywords: lipopeptides, staphylococci, enterococci
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
P. Gerber, A. Stucki, F. Acosta, M. Cottagnoud, and P. Cottagnoud
Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis
J. Antimicrob. Chemother., April 1, 2006; 57(4): 720 - 723.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. J. Skiest
Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin
J. Clin. Microbiol., February 1, 2006; 44(2): 655 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
I. I. Raad, H. A. Hanna, M. Boktour, G. Chaiban, R. Y. Hachem, T. Dvorak, R. Lewis, and B. E. Murray
Vancomycin-Resistant Enterococcus faecium: Catheter Colonization, esp Gene, and Decreased Susceptibility to Antibiotics in Biofilm
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5046 - 5050.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. A. Schriever, C. Fernandez, K. A. Rodvold, and L. H. Danziger
Daptomycin: A novel cyclic lipopeptide antimicrobial
Am. J. Health Syst. Pharm., June 1, 2005; 62(11): 1145 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. N. Steenbergen, J. Alder, G. M. Thorne, and F. P. Tally
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
J. Antimicrob. Chemother., March 1, 2005; 55(3): 283 - 288.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. E Stein, S. L Schooley, C. A Peloquin, V. Kak, D. H Havlichek, D. M Citron, K. L Tyrrell, and E. J. Goldstein
Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis
Ann. Pharmacother., March 1, 2005; 39(3): 427 - 432.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Fuda, M. Suvorov, S. B. Vakulenko, and S. Mobashery
The Basis for Resistance to {beta}-Lactam Antibiotics by Penicillin-binding Protein 2a of Methicillin-resistant Staphylococcus aureus
J. Biol. Chem., September 24, 2004; 279(39): 40802 - 40806.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.